Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Gives Progress Report On Risk Communication Plan

Executive Summary

About a year into the implementation of FDA's risk communication plan, the agency has met most of its 2010 goals, such as publishing a risk communication research agenda, designing surveys about public understanding and improving procedures to test communications more quickly.

You may also be interested in...



FDA’s Latest Communication Project Is Grant Opportunity For Non-profits

The agency is offering a modest $200,000 grant to piggyback on efforts by non-profit groups to “foster better understanding of the work of CDER.”

Risk Communication To Less Accessible Audiences Will Remain An FDA, Not Industry, Responsibility

Even as it convenes an advisory committee to discuss the issue, FDA doesn't intend to issue new regulation on risk communications with these segments of the population.

Risk Communication To Less Accessible Audiences Will Remain An FDA, Not Industry, Responsibility

Even as it convenes an advisory committee to discuss the issue, FDA doesn't intend to issue new regulation on risk communications with these segments of the population.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel